

This article was downloaded by:

On: 28 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713618290>

Novel Bioreversible Prodrugs of Clodronate

Marko Ahlmark^a; Tomi Järvinen^b; Hannu Taipale^b; Riku Niemi^b; Jouko Vepsäläinen^a

^a Dept. Chem., Univ. Kuopio, Kuopio, FINLAND ^b Dept. Pharmaceutical Chem., Univ. Kuopio, Kuopio, FINLAND

To cite this Article Ahlmark, Marko , Järvinen, Tomi , Taipale, Hannu , Niemi, Riku and Vepsäläinen, Jouko(1999) 'Novel Bioreversible Prodrugs of Clodronate', *Phosphorus, Sulfur, and Silicon and the Related Elements*, 147: 1, 419

To link to this Article: DOI: 10.1080/10426509908053689

URL: <http://dx.doi.org/10.1080/10426509908053689>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.


The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Novel Bioreversible Prodrugs of Clodronate

MARKO AHLMARK^a, TOMI JÄRVINEN^b, HANNU TAIPALE^b,
 RIKU NIEMI^b and JOUKO VEPSÄLÄINEN^a

^aDept. Chem. and ^bDept. Pharmaceutical Chem., Univ. Kuopio, P.O.Box 1627,
 FIN-70211 Kuopio FINLAND

Clodronate (**1**) belongs to family of bisphosphonates which are used to inhibit mineralization of soft tissues as well as bone formation and resorption disorders.[1] The clinical use of bisphosphonates is limited due to their poor bioavailability which is mostly attributed to their hydrophilic structure. More lipophilic molecules are obtained if some or all of the anionic sites are converted to covalent bonds. We herein report a new prodrug serie for clodronate: the anhydrides **2** and **3**. Previously we have reported that the simple alkyl esters **4** do not release clodronate via chemical or enzymatic hydrolysis.[2] The prepared new derivatives are stable in water (pH 5-7.5) but clodronate is relased rapidly with enzymatic hydrolysis.



The target clodronate dianhydrides were prepared with high selectivity and reasonable yields (34-74%) from tetrasodium clodronate by using a large excess of corresponding acid anhydride at elevated temperature.

The synthesized Cl₂MBP dianhydride derivatives fullfill the criteria of prodrug: 1) compounds were rather stable against chemical hydrolysis, 2) enzymatic hydrolyses were very fast and 3) all the compounds showed to be more lipophilic than clodronate.

References

- [1] O.L.M. Bijvoet, H.A. Fleisch, R.E. Canfield, R.G.G. Russell, Eds., *Bisphosphonate on Bones*, Elsevier, Amsterdam 1995.
- [2] R. Niemi, H. Taipale, M. Ahlmark, J. Vepsäläinen, T. Järvinen, *J. Chromatography B* **701**, 97, (1997).